The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China

被引：12

作者：

Wang B.C.M. ^{[1
]}

Liu D. ^{[2
]}

Furnback W.E. ^{[1
]}

Bifa F. ^{[3
]}

Dong P. ^{[2
]}

Xie L. ^{[2
]}

Guzauskas G.F. ^{[1
]}

Zhang S. ^{[2
]}

机构：

[1] Elysia Group, LLC, New York, NY

[2] Pfizer Investment Co., Ltd, Beijing

[3] China-Japan Friendship Hospital, Beijing

来源：

Pain and Therapy | 2016年 / 5卷 / 1期

关键词：

Cost-effectiveness; Gabapentin; Peripheral neuropathic pain (pNeP); Postherpetic neuralgia (PHN); Pregabalin;

D O I：

10.1007/s40122-016-0048-z

中图分类号：

学科分类号：

摘要：

Introduction: Postherpetic neuralgia (PHN), a type of peripheral neuropathic pain (pNeP), is the most common complication of herpes zoster. The objective of this analysis was to determine the cost-effectiveness of pregabalin compared with gabapentin in pNeP and PHN in China. Methods: We developed a China-localized 12-week simulation model to determine the cost-effectiveness of pregabalin compared to gabapentin in 1000 patients with pNeP and PHN. We utilized a questionnaire of Chinese key opinion leaders to estimate the pre-treatment distribution of pain scores for pNeP and PHN. Treatment outcomes for pregabalin and gabapentin were acquired from the published literature. Results: Treatment with pregabalin lead to 12-week decreases in pain scores of 0.6 (pNeP) and 0.7 (PHN) when compared to patients receiving gabapentin, at an incremental cost per additional day of mild/no pain of $45. The difference in mean days of no or mild pain, moderate pain, and severe pain was 8.8, −5.7, and −3.1, when comparing pregabalin and gabapentin, respectively. Pregabalin had more mean days with a >30% (7.71 days), 40% (8.97 days), and 50% reduction (9.97 days) in pain when compared with gabapentin. In the pNeP scenario, pregabalin was associated with a lower average pain score compared with gabapentin (3.91 vs. 4.55). The difference in mean days of no or mild pain, moderate pain, and severe pain was 9.39, −5.56, and −3.82, when comparing pregabalin and gabapentin, respectively. Pregabalin had more mean days with a >30% (8.77 days), 40% (9.81 days), and 50% reduction (10.55 days) in pain when compared with gabapentin. Conclusion: Pregabalin is an effective treatment for PHN and even for pNeP extensively, but at increased cost. It leads to improved outcomes including lower pain scores and more days with no or mild pain. Funding: Pfizer, China. © 2016, The Author(s).

引用

页码：81 / 91

页数：10

共 22 条

[1]

Haythornthwaite J.A., Benrud-Larson L.M., Psychological aspects of neuropathic pain, Clin J Pain, 16, pp. S101-S105, (2000)

[2]

Zhang Y., Feng Y., Qu Z., Qi Y., Zhan S., Current situation and challenge of registry in China, Front Med, 8, pp. 294-299, (2014)

[3]

McDermott A.M., Toelle T.R., Rowbotham D.J., Schaefer C.P., Dukes E.M., The burden of neuropathic pain: results from a cross-sectional survey, Eur J Pain, 10, 2, pp. 127-135, (2006)

[4]

Vera-Llonch M., Dukes E., Delea T.E., Wang S.T., Oster G., Neuropathic Pain Outcomes Modeling Working Group, Treatment of peripheral neuropathic pain: a simulation model, Eur J Pain, 10, 3, pp. 279-285, (2006)

[5]

Tarride J.E., Gordon A., Vera-Llonch M., Dukes E., Rousseau C., Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective, Clin Ther, 28, 11, pp. 1922-1934, (2006)

[6]

Gordon J., Lister S., Prettyjohns M., McEwan P., Tetlow A., Gabriel Z., A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain, J Med Econ., 15, 2, pp. 207-218, (2012)

[7]

Rodriguez M.J., Diaz S., Vera-Llonch M., Dukes E., Rejas J., Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia, Curr Med Res Opin, 23, 10, pp. 2585-2596, (2007)

[8]

Wang B.C., Liu D., Furnback W., Bifa F., Dong P., Xie L., Zhang S., Assessing the treatment of peripheral neuropathic pain (Pnep) and postherpetic neuralgia (Phn) in China using a simulation model, Value Health, 18, 7, (2015)

[9]

Freynhagen R., Strojek K., Griesing T., Whalen E., Balkenohl M., Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens, Pain, 115, pp. 254-263, (2005)

[10]

Rosenstock J., Tuchman M., LaMoreaux L., Sharma U., Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial, Pain, 110, pp. 628-638, (2004)

← 1 2 3 →